Vaccinating the world against the coronavirus is a lucrative business, and the shifting winds of the pandemic have big implications for the competitive landscape of vaccine makers. In the U.S., the delta variant accounts for 83% of new cases. By all indications, it’s fiercer and more difficult to protect against than prior variants and the original SARS-CoV-2 virus.
That means there’s more pressure than ever for vaccines to do their jobs well. But rather than disrupting the emerging status quo of the vaccine market, it looks like the delta variant is going to intensify the trends of consolidation that already exist.
Image source: Getty Images.
Why the delta variant matters
The principal reason why the vaccine landscape is changing is that some of the products on the market seem to be more effective against the delta variant than others. The two-dose jabs made by Moderna ( NASDAQ:MRNA ) and Pfizer ( NYSE:PFE ) remain the gold standard for generating durable immunity against the coronavirus.
But against the delta variant , both are likely to struggle. Preliminary data from the Israeli Ministry of Health suggests that Pfizer’s vaccine could be only 39% effective at preventing symptomatic infections from the variant, though it remains 91% effective against the risk of severe illness. Though there isn’t any high-quality data describing the efficacy of Moderna’s offering at the population level, the company’s initial data indicates that there is likely a similar reduction in protectiveness.
If that sounds like bad news for Pfizer and Moderna shareholders, it isn’t . The vaccines made by Johnson & Johnson ( NYSE:JNJ ) and AstraZeneca ( NASDAQ:AZN ) appear to perform even worse against the variant. In fact, they’re suspected of performing so much worse that public health officials in places like Italy are allowing certain people who have received jabs of these two vaccines to get booster shots of Pfizer or Moderna. This hodgepodge vaccination solution is supported by a growing body of evidence, and it’s bad news for AstraZeneca as well as Johnson & Johnson.
Because these two vaccines don’t perform as well against the delta variant, it’s hard to see high demand for them among the developed countries that can afford to be picky. And because it doesn’t look like its offering is effective enough when used in its standard two-dose regimen, there’s a good chance that AstraZeneca specifically will miss out on future income from sales of booster shots. In contrast, Moderna and Pfizer will probably see rising demand for their doses , thereby stealing market share directly from the competition.
If global public health officials endorse the need for booster doses, as many expect them to (eventually) do, it’s unlikely that either Johnson & Johnson or AstraZeneca investors will see much gain. On the other hand, such a ruling would probably juice the stock of the two mRNA vaccine makers even more.
Will updated jabs make a difference to shareholders?
Pfizer, AstraZeneca, and Johnson & Johnson all have a vast portfolio of medicines, and coronavirus vaccine revenue is only a small part of their overall value proposition to shareholders . Still, these companies are working to make their jabs as competitive as possible in anticipation of selling boosters in the near future.
AstraZeneca is currently working on a new version of its vaccine intended to protect against the beta variant, to be used either as a booster shot or as a full course of two jabs for unvaccinated people. The project is currently in late-stage clinical trials, but it appears doomed to be out of date by the time it gets approved for sale.
Pfizer will likely have more success with its effort to design a booster, as it’s targeting the delta variant specifically. But it might not start clinical trials until August, so it could still miss the window for its new vaccine to be relevant depending on how the pandemic proceeds. Either way, its product will continue to be in demand.
Nonetheless, when it comes to the value of coronavirus vaccine maker stocks, Moderna has been the largest winner by a mile, and the delta variant surge seems to be increasing that trend. Given that nearly all of its revenue is derived from sales of its vaccine, it’s hard to see how that could change. And if its early-stage booster shot project goes as planned, it might just be getting started.
- Race for Coronavirus Vaccine Heats Up Amid Growing Global Death Toll and Nations on Lockdowns
- First patient will get an experimental coronavirus vaccine TODAY – but scientists warn it will be at least a YEAR before the jab could be rolled out to the rest of the world
- How Trump's rhetoric has changed as coronavirus spread
- A coronavirus vaccine trial in humans has begun. When could a COVID-19 shot be available?
- Coronavirus vaccines and treatment: Everything you need to know
- Pharma firm Anges and Osaka University to begin testing coronavirus vaccine on animals
- We need a coronavirus vaccine — I just wish we could afford it
- Trump signals change in coronavirus strategy that could clash with health experts
- Government official: Coronavirus vaccine trial starts Monday
- Coronavirus vaccine test opens as US volunteer gets 1st shot
- Trump's attempt to buy a coronavirus vaccine shows why big pharma needs to change
- Coronavirus Vaccine Trial Gives Dose to First Participant
- Johnson & Johnson CEO on potential coronavirus vaccine: 'I think we'll have important data by the end of the year'
- Meet the company that has just begun testing a coronavirus vaccine in the United States
- How the world will change after coronavirus
- Coronavirus: Should stock markets be shut down until the crisis eases?
- The world is coming together to fight coronavirus. It can do the same for the climate crisis
- Coronavirus: the week explained
- Covid-19 outbreak: How people across the world are tackling the crisis
- What you need to know about coronavirus on Tuesday, March 17
How the Delta Variant Could Change the World of Coronavirus Vaccine Stocks have 971 words, post on www.fool.com at August 3, 2021. This is cached page on Business News. If you want remove this page, please contact us.